These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22331080)

  • 1. IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells.
    Burkhardt UE; Sloots A; Jakobi V; Wei WZ; Cavallo F; Kloke BP; Wels WS
    Cancer Immunol Immunother; 2012 Sep; 61(9):1473-84. PubMed ID: 22331080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity.
    Rohrbach F; Weth R; Kursar M; Sloots A; Mittrücker HW; Wels WS
    J Immunol; 2005 May; 174(9):5481-9. PubMed ID: 15843546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
    Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
    Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing vaccine potency through exosome antigen targeting.
    Hartman ZC; Wei J; Glass OK; Guo H; Lei G; Yang XY; Osada T; Hobeika A; Delcayre A; Le Pecq JB; Morse MA; Clay TM; Lyerly HK
    Vaccine; 2011 Nov; 29(50):9361-7. PubMed ID: 22001882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
    Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
    Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene.
    Gerstmayer B; Altenschmidt U; Hoffmann M; Wels W
    J Immunol; 1997 May; 158(10):4584-90. PubMed ID: 9144470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct.
    Roth A; Rohrbach F; Weth R; Frisch B; Schuber F; Wels WS
    Br J Cancer; 2005 Apr; 92(8):1421-9. PubMed ID: 15812545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhance the anti-renca carcinoma effect of a DNA vaccine targeting G250 gene by co-expression with cytotoxic T-lymphocyte associated antigen-4(CTLA-4).
    Zhao Y; Wei Z; Yang H; Li X; Wang Q; Wang L; Li S
    Biomed Pharmacother; 2017 Jun; 90():147-152. PubMed ID: 28351777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A DNA vaccine against cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) prevents tumor growth.
    Lan KH; Liu YC; Shih YS; Tsaid CL; Yen SH; Lan KL
    Biochem Biophys Res Commun; 2013 Oct; 440(2):222-8. PubMed ID: 24041689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.
    Pakravan N; Hashemi SM; Hassan ZM
    Cell Stress Chaperones; 2011 Jan; 16(1):41-8. PubMed ID: 20730610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors.
    Tegerstedt K; Lindencrona JA; Curcio C; Andreasson K; Tullus C; Forni G; Dalianis T; Kiessling R; Ramqvist T
    Cancer Res; 2005 Jul; 65(13):5953-7. PubMed ID: 15994974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M; Weth R; Wels WS
    J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
    Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
    Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
    J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative efficacy of CTLA-4 and L-selectin targeted DNA vaccines in mice and sheep.
    Drew DR; Boyle JS; Lew AM; Lightowlers MW; Chaplin PJ; Strugnell RA
    Vaccine; 2001 Aug; 19(31):4417-28. PubMed ID: 11483267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice.
    Cao J; Jin Y; Li W; Zhang B; He Y; Liu H; Xia N; Wei H; Yan J
    BMC Immunol; 2013 Aug; 14():39. PubMed ID: 23941509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.